---

Article-by-Article Scoring

---

Article 1 — Lee et al., cfDNA methylation classifier, prostate cancer (PMID 42801083)

Dimension	Score	Rationale
Scientific Novelty	7	Targeted cfDNA methylation classifiers for PCa/BPH discrimination are an active but still-emerging space; the combination of promoter-proximal and gene-body methylation profiling with GO-level biological plausibility is a meaningful methodological contribution
Clinical Relevance	8	PSA non-specificity is one of the most consequential diagnostic limitations in urology; a liquid biopsy classifier that reduces unnecessary biopsies addresses a very concrete clinical need
Population Reach	8	Prostate cancer is the most common non-skin cancer in men globally; tens of millions undergo PSA testing annually
Implementation Speed	4	Abstract-only; cohort sizes unconfirmed; will require prospective clinical validation, regulatory clearance, and lab infrastructure
Evidence Strength	5	Observational biomarker development/validation; abstract-only review; no AUC or sensitivity/specificity reported in the triage metadata; classification_confidence = medium

Key quantitative result: Not reported in available abstract (AUC, sensitivity, specificity not extracted). External validation: Not confirmed from abstract alone. Main limitation: Abstract-only; sample sizes unknown; retrospective design likely; no head-to-head comparison with PSA + MRI standard-of-care. Equity: Prostate cancer disproportionately affects Black men, who also have higher rates of PSA non-specificity and biopsy complications — a validated cfDNA classifier could disproportionately benefit this group if equitably deployed; cost and lab access remain barriers in low-resource settings. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 2 — Khanom et al., HPV-16/18 E6 mRNA triage, cervical cancer (PMID 42801821)

Dimension	Score	Rationale
Scientific Novelty	6	HPV E6/E7 mRNA triage as a concept is not new; the novelty here is an in-house semi-quantitative fold-change assay designed specifically for LMIC affordability and accessibility
Clinical Relevance	8	Cervical cancer kills ~350,000 women per year globally, overwhelmingly in LMICs; a sensitive, specific triage tool that distinguishes CIN3/cancer from lower-grade lesions fills a genuine gap
Population Reach	9	Hundreds of millions of women in HPV-endemic, resource-limited settings stand to benefit; cervical cancer is almost entirely preventable with adequate screening and triage
Implementation Speed	5	Semi-quantitative real-time PCR is technically accessible in many LMIC reference labs; however, further validation, WHO prequalification, and health system integration are needed
Evidence Strength	5	Assay development and validation study; abstract-only; 95.24% sensitivity and 86.36% specificity at E6 FC ≥0.648 cutoff reported but cohort size unconfirmed; classification_confidence = medium

Key quantitative result: E6 FC ≥0.648 → 95.24% sensitivity, 86.36% specificity for CIN3+. External validation: Not confirmed; single-site LMIC study. Main limitation: Single-center; sample size unconfirmed; assay not commercially standardized; performance in varied HPV co-infection backgrounds unknown. Equity: Explicitly designed for under-resourced settings — one of the most equity-positive studies in this batch. Western high-income markets already have validated commercial triage tools; this fills the gap where they are unavailable. Evidence Maturity (confirmed/revised): Exploratory ✓ (but higher equity weight than triage score suggests)

---

Article 3 — Rosini et al., digital PCR BAP1/MTAP, mesothelioma (PMID 42801547)

Dimension	Score	Rationale
Scientific Novelty	7	Applying digital PCR to cell-free DNA from pleural fluid supernatant (rather than tissue) for BAP1/MTAP copy-number loss is a technically novel approach; moving from IHC to liquid-biopsy-adjacent methodology in pleural effusion is genuinely incremental to current practice
Clinical Relevance	7	Mesothelioma is notoriously difficult to diagnose; current approaches require tissue biopsy with procedural risk; improving diagnostic sensitivity from 86.5% to 91.9% in an already-confirmed cohort is modest but meaningful for a rare, fatal cancer
Population Reach	4	Mesothelioma is rare (~30,000 new cases/year globally); however, Population Reach adjusted for unmet need in rare disease context is moderate-high — there is essentially no effective early diagnostic tool
Implementation Speed	5	Digital PCR platforms are increasingly available in tertiary centers; however, this is a retrospective study of n=37; prospective validation in diagnostically uncertain cases needed before adoption
Evidence Strength	6	Retrospective design with n=37 limits power; classification_confidence = high; both modalities (IHC + dPCR) evaluated on same samples allowing direct comparison; prospective pilot in 6 undetermined cases is an encouraging addendum

Key quantitative result: Diagnostic sensitivity improved from 86.5% (IHC alone) to 91.9% (IHC + dPCR combined). External validation: None; single-center retrospective. Main limitation: Very small n=37; retrospective; all patients were already confirmed PM — performance in truly diagnostically uncertain cases is the clinically relevant question. Equity: Mesothelioma disproportionately affects blue-collar workers (shipbuilders, miners, construction workers) in high-asbestos-exposure countries, including many low-income communities; improving access to non-invasive diagnostics has equity value. However, digital PCR platforms are expensive and may not be available in lower-resource settings. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 4 — Mitsudomi et al., perioperative durvalumab NSCLC AEGEAN (PMID 42802029)

Dimension	Score	Rationale
Scientific Novelty	6	Perioperative PD-L1 blockade in resectable NSCLC is an established and approved strategy globally (AEGEAN results published 2023); this is an important but expected Japanese subgroup confirmation
Clinical Relevance	8	Perioperative immunotherapy is an active area of guideline evolution; Japanese-specific data inform prescribing in a population where ethnic pharmacogenomic differences and distinct regulatory pathways matter
Population Reach	7	NSCLC is the leading cause of cancer death globally; resectable disease represents ~30% of NSCLC; the Japanese subgroup is clinically relevant but limits global reach of this specific analysis
Implementation Speed	7	Durvalumab is already FDA/EMA/PMDA-approved; Japanese regulators can integrate subgroup data rapidly; prescribers can act on this quickly
Evidence Strength	7	Phase 3 RCT subgroup (prespecified exploratory); n=79 limits statistical power for subgroup conclusions but consistent with global trial; RCT framework provides strong methodological foundation

Key quantitative result: Improved event-free survival and pCR vs chemotherapy alone (specific HRs/ORs not extracted from abstract). External validation: Global AEGEAN trial results corroborate; subgroup is internally consistent. Main limitation: n=79 subgroup; exploratory analysis; not powered for definitive subgroup conclusions. Equity: Japanese patients are underrepresented in global oncology trials; this subgroup analysis specifically addresses that gap. The broader question of access to perioperative immunotherapy in lower-income countries remains unresolved. Evidence Maturity (confirmed/revised): Potentially Practice-Changing ✓

---

Article 5 — Chohan et al., N-AVD vs BV-AVD Hodgkin lymphoma (PMID 42802099)

Dimension	Score	Rationale
Scientific Novelty	5	Both regimens are established; real-world comparative data adds to existing RCT knowledge but is not mechanistically novel
Clinical Relevance	8	Choosing between N-AVD and BV-AVD is a genuine front-line clinical decision; this data directly informs toxicity profiling for that decision
Population Reach	6	Advanced Hodgkin lymphoma affects relatively younger patients (~15-35 years predominantly); ~86,000 new cases globally per year
Implementation Speed	8	Both drugs are approved and in use; this real-world data can immediately inform monitoring protocols and growth factor prophylaxis decisions
Evidence Strength	6	Large multicenter real-world cohort (n=646, 17 centers); retrospective design limits causal inference; no randomization; selection bias possible; classification_confidence = high

Key quantitative result: N-AVD neutropenia 77.2% vs BV-AVD 43.9%; comparable survival; dose reductions more common with BV-AVD. External validation: Consistent with SWOG S1826 trial findings favoring N-AVD. Main limitation: Retrospective, observational; center selection bias; no OS maturity data. Equity: Includes pediatric and adult populations across 17 US centers; data on race/ethnicity and insurance status not reported in abstract. Evidence Maturity (confirmed/revised): Validated ✓

---

Article 6 — Einarsdottir et al., respiratory viral infections post-CAR-T (PMID 42801991)

Dimension	Score	Rationale
Scientific Novelty	6	Infectious complications post-CAR-T are well-recognized; the novel contributions here are the ALC <0.5 ×10⁹/L threshold, timing characterization, and cross-product analysis across lymphoma and myeloma
Clinical Relevance	8	Respiratory viral infections are a leading cause of non-relapse mortality post-CAR-T; identifying immunological predictors enables actionable monitoring and prophylaxis
Population Reach	6	CAR-T recipients number in the tens of thousands annually and are growing rapidly; but still a specialized population
Implementation Speed	7	ALC monitoring is routine; the threshold finding is immediately applicable to clinical surveillance protocols at CAR-T centers
Evidence Strength	6	Large retrospective cohort (n=563, 2018-2024); multicenter; retrospective design; abstract-only review

Key quantitative result: ALC <0.5 ×10⁹/L as a clinically relevant threshold for LRTI risk. External validation: Not stated; single-institution (MSKCC implied by author affiliations). Main limitation: Retrospective; single or limited centers; causality unestablished. Equity: CAR-T therapy access remains highly unequal globally and within the US; findings primarily apply to patients at major academic centers. Evidence Maturity (confirmed/revised): Validated ✓

---

Article 7 — Hagiwara et al., resolved HBV and DLBCL outcomes JCOG0601 (PMID 42801438)

Dimension	Score	Rationale
Scientific Novelty	5	The question of HBV history in rituximab-treated lymphoma is well-studied; this adds RCT-derived clarification but is confirmatory rather than groundbreaking
Clinical Relevance	7	Clinicians commonly face uncertainty about HBV prophylaxis decisions in anti-HBc-positive, HBsAg-negative DLBCL patients; this provides reassuring, well-designed evidence
Population Reach	7	HBV is endemic in East Asia, sub-Saharan Africa, and parts of South America; anti-HBc positivity is extremely common in these populations — this finding is globally relevant
Implementation Speed	7	RCT-based supplementary analysis; data can immediately inform antiviral prophylaxis decisions and reduce unnecessary treatment
Evidence Strength	7	Uses randomized trial data (JCOG0601); supplementary analysis limits primary endpoint power but design quality is high relative to observational comparators

Key quantitative result: Anti-HBc positivity did not significantly affect PFS or OS in HBsAg-negative DLBCL on R-CHOP. External validation: Consistent with prior observational studies; RCT framework provides stronger support. Main limitation: Supplementary analysis; sample size of anti-HBc-positive subgroup not confirmed from abstract. Equity: Directly relevant to East Asian and sub-Saharan African populations, where HBV prevalence is highest; these populations are often underrepresented in lymphoma trials. Evidence Maturity (confirmed/revised): Validated ✓

---

Article 8 — Hu et al., PCR-free biosensor cfDNA methylation, ovarian cancer (PMID 42801800)

Dimension	Score	Rationale
Scientific Novelty	8	Eliminating both PCR amplification and bisulfite conversion while achieving 208 aM LOD via nanoconfined electrochemical transduction is technically innovative and addresses two major pain points in cfDNA methylation detection
Clinical Relevance	3	In vitro proof-of-concept only; no clinical samples validated; non-human study cap applied
Population Reach	6	Ovarian cancer affects ~320,000 women/year globally; early detection is a critical unmet need
Implementation Speed	2	Lab-stage only; multiple translation steps required (clinical samples, regulatory, manufacturing)
Evidence Strength	4	In vitro proof-of-concept; no clinical validation; capped per non-human study rules

Key quantitative result: LOD 208 aM; high specificity claimed. External validation: None; single-lab proof-of-concept. Main limitation: Entirely in vitro; no human clinical samples; biosensor-to-clinical translation is notoriously challenging. Equity: If translated, a low-cost, amplification-free assay could improve equity by reducing infrastructure requirements — but this is speculative at this stage. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 9 — Kim et al., ctDNA methylation prostate cancer staging (PMID 42801146)

Dimension	Score	Rationale
Scientific Novelty	7	Two-marker ctDNA methylation signature (C2orf88 + HAPLN3) distinguishing localized from metastatic PCa is a specific and novel biomarker finding with potential precision oncology application
Clinical Relevance	7	Accurately distinguishing localized from metastatic PCa non-invasively would directly guide intensification of systemic therapy vs local treatment — a high-stakes decision
Population Reach	7	Prostate cancer is extraordinarily common; imaging-equivocal cases are numerous
Implementation Speed	4	n=174 observational; prospective validation needed; no comparative data vs. PSMA-PET or standard imaging
Evidence Strength	5	Observational; n=174; abstract-only; classification_confidence = high; specific markers identified but external validation not confirmed

Key quantitative result: Two-marker signature (C2orf88 + HAPLN3) significantly increases with advancing disease stage; accuracy metrics not extracted. External validation: None confirmed. Main limitation: Observational; single institution likely; no head-to-head comparison with state-of-the-art PSMA-PET imaging. Equity: Liquid biopsy approaches are potentially more equitable than advanced imaging for staging in low-resource settings; however, methylation profiling still requires laboratory infrastructure. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 10 — Foong et al., intrathecal dexamethasone in FIRES (PMID 42801909)

Dimension	Score	Rationale
Scientific Novelty	7	Intrathecal dexamethasone for FIRES is a novel route of administration for an established drug in a disease with essentially no established treatment protocol; the dose-response signal (≥1 mg/kg) is actionable
Clinical Relevance	7	FIRES has near-zero treatment options beyond ketogenic diet and immunotherapy attempts; 39.1% achieving favorable functional outcomes is clinically meaningful in this context
Population Reach	3	FIRES is extremely rare (estimated <1 per million); however, Population Reach adjusted for unmet need in rare disease context is proportionally high
Implementation Speed	5	Intrathecal dexamethasone is a known drug, available in most hospital formularies; the barrier is procedural skill and evidence base, not drug availability
Evidence Strength	4	Review/case series synthesis; sample size unconfirmed; no randomized comparison; classification_confidence = medium

Key quantitative result: 39.1% favorable functional outcomes; cumulative dose ≥1 mg/kg significantly associated with better outcomes (p=0.048). External validation: None; case series review. Main limitation: No control arm; small patient numbers; heterogeneous patient populations across published cases. Equity: FIRES affects children and adolescents, including in low-resource settings where ICU-level care and advanced immunotherapies are unavailable; intrathecal dexamethasone is accessible and relatively inexpensive. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 11 — Del Brutto et al., hypertensive retinopathy and WMH progression (PMID 42801966)

Dimension	Score	Rationale
Scientific Novelty	6	The retina-brain vascular parallel is established; 10-year prospective data strengthening this link in a population-based setting adds meaningful longitudinal evidence
Clinical Relevance	7	Fundus photography is widely available and performed; if retinopathy grade reliably predicts WMH progression, this is immediately actionable for risk stratification and blood pressure treatment intensification
Population Reach	8	Hypertension affects ~1.3 billion people globally; retinopathy and WMH burden are substantial in this population
Implementation Speed	7	Fundoscopy/retinal photography is already part of hypertension workup in many guidelines; integrating WMH risk stratification requires only clinical awareness change
Evidence Strength	7	Prospective 10-year population-based cohort; n=241; Ecuador-specific generalizability questions; sensitivity analyses reported; classification_confidence = high

Key quantitative result: Baseline hypertensive retinopathy grade independently predicted WMH progression (specific OR/HR not extracted from abstract). External validation: Consistent with cross-sectional literature but prospective confirmation adds substantially. Main limitation: n=241; single geographic site (Ecuador); generalizability to diverse hypertensive populations unclear. Equity: Ecuador-based study provides data from a Latin American population, underrepresented in cerebrovascular research — a genuine equity contribution. However, the practical utility of MRI follow-up for WMH progression is limited in low-resource settings. Evidence Maturity (confirmed/revised): Validated ✓

---

Article 12 — Xiao et al., nocturia and CKM syndrome mortality (PMID 42801412)

Dimension	Score	Rationale
Scientific Novelty	6	CKM syndrome as a formal AHA framework is relatively new (2023); mapping nocturia onto CKM stages is a novel application; the nocturia-mortality link in the general population is less novel
Clinical Relevance	7	Nocturia is an underappreciated symptom in cardiovascular risk assessment; this large dataset provides evidence to elevate it as a clinical screening prompt
Population Reach	9	CKM syndrome stages 0-4 encompass the vast majority of middle-aged and older adults in the US and globally; the NHANES backbone provides representative population data
Implementation Speed	7	Nocturia can be assessed with a single question; the barrier is awareness and clinical workflow integration, not technology
Evidence Strength	6	Dual-dataset design (NHANES n=11,910 + hospital cohort n=865) strengthens generalizability; cross-sectional NHANES component limits causal inference; mortality linkage in NHANES adds prospective element; abstract-only

Key quantitative result: Nocturia associated with significant all-cause and cardiovascular mortality risk across CKM stages (specific HRs not extracted). External validation: Hospital-based clinical validation cohort (n=865) provides some external validation. Main limitation: Cross-sectional NHANES component; nocturia self-reported; confounders (sleep apnea, medications) may not be fully adjusted. Equity: NHANES is US-representative; findings most applicable to US adults. Nocturia screening is equitable — it costs nothing and requires no technology. Evidence Maturity (confirmed/revised): Validated ✓

---

Article 13 — Bai & Yan, ApoB-LDL discordance, NHANES (PMID 42801018)

Dimension	Score	Rationale
Scientific Novelty	5	ApoB-LDL discordance is a well-recognized phenomenon; mapping it to AHA PREVENT risk categories is a new angle but not mechanistically novel
Clinical Relevance	7	Identifying patients with falsely reassuring LDL-C who need ApoB testing has direct therapeutic implications (statin intensification, PCSK9 inhibitor candidacy)
Population Reach	8	Applies to tens of millions of US adults without prevalent CVD who undergo routine lipid testing
Implementation Speed	7	ApoB testing is available in most clinical labs; the barrier is guideline integration and ordering culture, not technology
Evidence Strength	5	Cross-sectional NHANES (2005-2016); sample size not extracted from abstract; no longitudinal outcome data; classification_confidence = high

Key quantitative result: Discordantly high ApoB with normal LDL-C was prevalent in higher AHA PREVENT risk categories (specific prevalence rates not extracted). External validation: Consistent with prior ApoB discordance literature; no new external validation. Main limitation: Cross-sectional; cannot establish outcomes benefit of ApoB-guided treatment; NHANES 2005-2016 data may not reflect contemporary lipid-lowering treatment patterns. Equity: NHANES is US-representative; ApoB testing is broadly available but may be inconsistently covered by insurance for low-income patients. Evidence Maturity (confirmed/revised): Validated ✓

---

Article 14 — Hayashi & Masterson, food noise prevalence, US adults (PMID 42801078)

Dimension	Score	Rationale
Scientific Novelty	6	"Food noise" as a defined construct measured in a nationally representative sample is novel; the GLP-1 mechanism context adds contemporary relevance
Clinical Relevance	5	Descriptive prevalence data; not directly actionable for patient management but informs GLP-1 prescribing rationale and patient selection
Population Reach	8	Affects over 12% of US adults by self-report; GLP-1 use is rapidly expanding
Implementation Speed	5	Conceptual/definitional work; clinical implementation depends on future validation of food noise as a treatment target
Evidence Strength	5	Cross-sectional nationally representative survey; sample size not confirmed; self-report construct validity not fully established; classification_confidence = medium

Key quantitative result: ~12.68% of males report food noise; specific female prevalence and correlation coefficients not extracted. External validation: None; definitional construct needs further validation. Main limitation: Self-reported; construct not validated clinically; cross-sectional; causal direction unclear. Equity: US-representative but English-language survey; food preoccupation constructs may vary culturally. Evidence Maturity (confirmed/revised): Exploratory ✓ (triage listed as Exploratory correctly)

---

Article 15 — Wang et al., kidney function and cognitive impairment, CLHLS (PMID 42802142)

Dimension	Score	Rationale
Scientific Novelty	5	CKD-dementia association is well-established; this adds Chinese older adult longitudinal data confirming the finding
Clinical Relevance	6	Reinforces kidney function monitoring as part of dementia prevention strategy; modifiable pathway
Population Reach	9	Chinese elderly ≥65 represent the world's largest aging cohort; CKD is highly prevalent; the CLHLS is a nationally representative dataset
Implementation Speed	6	eGFR and ACR measurement are routine; clinical awareness of the CKD-cognition link can immediately prompt monitoring
Evidence Strength	6	Longitudinal cohort (CLHLS, 2011-2014); nationally representative; sample size unconfirmed from abstract; abstract-only; classification_confidence = high

Key quantitative result: eGFR <60 mL/min/1.73m² and elevated ACR independently associated with increased cognitive impairment risk (specific ORs not extracted). External validation: Consistent with global literature on CKD-dementia. Main limitation: Two survey waves only (2011-2014); survivor bias likely; cognitive assessment method not detailed in abstract. Equity: China-specific but globally relevant; CKD is more prevalent in underserved populations with reduced healthcare access. Evidence Maturity (confirmed/revised): Validated ✓

---

Article 16 — Zrineh et al., Alzheimer's disease review, lecanemab/donanemab (PMID 42801246)

Dimension	Score	Rationale
Scientific Novelty	3	Narrative review synthesizing lecanemab (approved 2023) and donanemab (approved 2024) approvals; these are not new findings
Clinical Relevance	7	Practitioners need accessible synthesis of AD disease-modifying therapy to guide early AD diagnosis, patient selection, and ARIA monitoring
Population Reach	9	~55 million people live with dementia globally; AD is the leading cause; aging populations worldwide
Implementation Speed	5	Drugs are approved but access is highly unequal; ARIA monitoring infrastructure, amyloid testing, and high drug costs limit real-world adoption
Evidence Strength	4	Narrative review; no new primary data; design_quality = low; classification_confidence = high

Key quantitative result: Lecanemab and donanemab modestly but significantly slow clinical decline (specific effect sizes from trials not re-reported in abstract). External validation: Based on FDA-approved pivotal trial data (CLARITY AD, TRAILBLAZER-ALZ 2). Main limitation: Narrative review, not systematic; no new data; existing trials excluded moderate-to-severe AD and patients with comorbidities common in real-world populations. Equity: Anti-amyloid antibodies are expensive (~$26,500/year for lecanemab); access is highly inequitable; minority populations underrepresented in pivotal trials; ARIA risk may differ across populations. Evidence Maturity (confirmed/revised): Validated ✓ (for the drugs reviewed; the review itself is Exploratory in synthesis quality)

---

Article 17 — Mulkareddy et al., EGPA diagnostic delay (PMID 42801333)

Dimension	Score	Rationale
Scientific Novelty	6	Systematic characterization of diagnostic delay and clinical predictors in EGPA at a single center; renal involvement as a protective factor against delay is a specific actionable finding
Clinical Relevance	7	Diagnostic delay in EGPA leads to organ damage; identifying predictors of delay has direct value for internists, pulmonologists, and allergists who may miss the diagnosis
Population Reach	3	EGPA has prevalence ~10-15 per million; very rare, but Population Reach adjusted for rare disease unmet need is moderate
Implementation Speed	6	Clinical predictors can immediately be incorporated into teaching and referral pathways
Evidence Strength	5	Retrospective single-center; sample size unconfirmed; classification_confidence = high

Key quantitative result: Renal involvement associated with lower likelihood of diagnostic delay (p=0.037). External validation: None; single-center. Main limitation: Single-center retrospective; referral bias; small sample likely. Equity: Rare disease with high unmet need; patients who lack access to specialty care experience the longest delays. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 18 — Gong et al., DOORS-GHF geriatric hip fracture risk score (PMID 42802133)

Dimension	Score	Rationale
Scientific Novelty	5	Geriatric surgical risk scores are numerous; DOORS-GHF is specifically calibrated for hip fracture, which adds clinical specificity
Clinical Relevance	7	Hip fracture in the elderly carries 20-30% one-year mortality; a well-calibrated preoperative risk tool has direct utility for anesthesia and surgical planning, ICU allocation, and family counseling
Population Reach	8	~1.6 million hip fractures annually worldwide; prevalence rising with aging populations; China faces a particularly dramatic burden
Implementation Speed	7	Risk scores are low-cost, low-tech, and immediately implementable once validated; the AUC of 0.878 for complications is clinically meaningful
Evidence Strength	6	Prospective development and multicenter validation; AUC 0.878; classification_confidence = medium; sample size not confirmed from abstract

Key quantitative result: AUC 0.878 for complication prediction; superior to DORSSSP v3.0 and P-POSSUM. External validation: External validation cohort described; multicenter. Main limitation: China-specific validation; may not generalize to Western populations with different comorbidity profiles; abstract-only. Equity: Hip fracture disproportionately affects the elderly poor; a free-to-use risk calculator improves care equity. Evidence Maturity (confirmed/revised): Validated ✓

---

Article 19 — Legrand & Duberg, exercise frequency and depression RCT (PMID 42802098)

Dimension	Score	Rationale
Scientific Novelty	5	Exercise for depression is well-established; dose-frequency effects have been explored; the specific quantification of a threefold CSI advantage for high-frequency exercise is a useful contribution
Clinical Relevance	7	Student mental health is a growing crisis; RCT evidence supporting high-frequency exercise directly informs university wellness program design
Population Reach	7	~300 million people live with depression globally; university student population is ~250 million worldwide
Implementation Speed	8	Exercise is immediately implementable with zero regulatory barriers; findings can be translated into program design today
Evidence Strength	7	Single-blind RCT; CSI analysis pre-specified; sample size not confirmed but sufficient for RCT design; classification_confidence = high

Key quantitative result: Clinically significant improvement in 38.9% (HFET) vs 22.2% (LFET) vs 11.1% (control); z=1.93, p=0.027. External validation: Consistent with meta-analytic literature on exercise dose-depression. Main limitation: Single-blind (not double-blind); sample size not confirmed; university student population may not generalize to all depressed adults; unclear exercise type and intensity. Equity: Exercise is low-cost and widely accessible; however, exercise access disparities exist along socioeconomic lines. Evidence Maturity (confirmed/revised): Validated ✓

---

Article 20 — Morita et al., FLT vs FDG PET for CNS lymphoma vs GBM (PMID 42801444)

Dimension	Score	Rationale
Scientific Novelty	6	FLT PET in CNS tumors is an active but non-mainstream area; comparative data vs FDG in the specific PCNSL-vs-GBM differential is useful
Clinical Relevance	6	CNS lymphoma vs GBM differentiation is a high-stakes diagnostic challenge; however, the conclusion of "no significant AUC difference" suggests FLT doesn't clearly improve on current standard
Population Reach	4	Both PCNSL and GBM are relatively rare; 58-patient dataset
Implementation Speed	4	FLT PET is not widely available; regulatory status varies; clinical uptake would require substantial infrastructure change
Evidence Strength	5	Retrospective; n=58; histologically confirmed; paired AUC comparison methodology is appropriate

Key quantitative result: No significant difference between paired AUCs of FLT and FDG PET for PCNSL vs GBM differentiation. External validation: None; single-center. Main limitation: Small n=58; retrospective; FLT not widely available. Equity: Specialized imaging technology; equity implications limited to specialized center access. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 21 — Masogo et al., AI lesion segmentation, lymphoma FDG PET/CT (PMID 42802086)

Dimension	Score	Rationale
Scientific Novelty	5	AI segmentation of FDG PET/CT in lymphoma is an active field; nnUNet-based architectures are established; the post-processing approach and quantitative concordance data are incremental
Clinical Relevance	6	Automated segmentation could reduce radiologist workload and standardize response assessment; "good-to-excellent" accuracy is clinically useful but needs prospective validation
Population Reach	6	Lymphoma is one of the most common hematologic malignancies; ~570,000 new cases globally per year
Implementation Speed	5	AI imaging tools are increasingly being integrated; regulatory clearance and workflow integration are rate-limiting steps
Evidence Strength	5	Retrospective validation; sample size not confirmed; abstract-only; classification_confidence = medium

Key quantitative result: Good-to-excellent lesion detection accuracy; high quantitative concordance with manual segmentation (specific Dice/F1 scores not extracted). External validation: Not confirmed. Main limitation: Retrospective; sample size unconfirmed; no prospective clinical impact evaluation. Equity: If deployed, AI segmentation could help resource-limited centers without expert nuclear medicine radiologists. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 22 — Saha et al., ML MRI in Friedreich ataxia (PMID 42802091)

Dimension	Score	Rationale
Scientific Novelty	7	Identifying distinct ML-derived MRI progression subtypes in Friedreich ataxia is genuinely novel and addresses a critical gap for trial design in a heterogeneous rare disease
Clinical Relevance	5	High importance for trial design and prognosis; less immediately actionable for clinical management today
Population Reach	3	Friedreich ataxia prevalence ~1:50,000; rare disease; adjusted for unmet need, moderate importance
Implementation Speed	4	Requires multimodal MRI + ML pipeline; not immediately implementable in most clinical settings
Evidence Strength	5	Longitudinal observational with ML analysis; sample size unconfirmed; classification_confidence = medium

Key quantitative result: MRI pattern clusters correlate with clinical and genetic factors (specific cluster characteristics not extracted). External validation: Not confirmed. Main limitation: Abstract-only; sample size unconfirmed; ML cluster stability and replication not confirmed. Equity: Rare disease with high unmet need; ML-based stratification could improve trial enrichment and ensure equitable representation across disease subtypes. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 23 — Guo et al., multi-phase CT DL for gastric GIST risk (PMID 42801804)

Dimension	Score	Rationale
Scientific Novelty	6	Multi-phase CT DL for GIST risk stratification is a logical extension of existing work; the cross-phase attention mechanism and external multicenter validation are methodological contributions
Clinical Relevance	7	Preoperative GIST risk stratification for 2-5 cm tumors (the "gray zone") directly informs whether laparoscopic vs open surgery or watchful waiting is appropriate
Population Reach	5	GISTs are relatively uncommon (~15,000 cases/year in the US); however globally significant, particularly in Asian populations where gastric GISTs are more prevalent
Implementation Speed	5	Requires CT acquisition protocol integration and DL model deployment; feasible in medium-to-large radiology departments
Evidence Strength	6	Multicenter external validation; n=427; AUC 0.735-0.812 externally (vs radiologists); retrospective; classification_confidence = high

Key quantitative result: External AUC 0.735-0.812; superior to radiologists (0.735-0.812 vs radiologist range). External validation: Multicenter external validation cohort included. Main limitation: Retrospective; China-specific centers; generalizability to non-Asian populations uncertain. Equity: CT-based (widely available); DL tool could standardize risk assessment across centers without expert radiologists. Evidence Maturity (confirmed/revised): Exploratory ✓ (multicenter validation moves it toward Validated; conservative given retrospective design)

---

Article 24 — Xing et al., PABCNet super-resolution coronary MRA (PMID 42801839)

Dimension	Score	Rationale
Scientific Novelty	7	Bayesian confidence quantification added to super-resolution DL for non-contrast coronary MRA addresses a specific clinical adoption barrier (reliability uncertainty); technically innovative
Clinical Relevance	5	Non-contrast coronary MRA is not yet mainstream; improving image quality is a necessary but insufficient step for clinical adoption
Population Reach	7	Coronary artery disease is the leading global cause of death; non-contrast MRA would benefit patients with contrast contraindications
Implementation Speed	3	MRI protocol changes, DL integration, and regulatory approval needed; coronary CTA and invasive angiography remain entrenched alternatives
Evidence Strength	5	Technical validation study; human patients but no clinical outcomes; classification_confidence = medium

Key quantitative result: Superior coronary clarity and artifact suppression vs. comparator methods by radiologist evaluation. External validation: None; single-center technical validation. Main limitation: No clinical outcome data; no comparative diagnostic accuracy vs coronary CTA; technical paper only. Equity: Non-contrast imaging would benefit CKD patients who cannot receive gadolinium — an underserved population. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 25 — Liu et al., ML metabolomics for MASLD (PMID 42801942)

Dimension	Score	Rationale
Scientific Novelty	6	Kynurenine and neopterin as MASLD biomarkers from tryptophan metabolism is a novel mechanistic insight; seven-algorithm ML comparison is methodologically sound
Clinical Relevance	6	MASLD diagnosis currently requires liver biopsy or imaging; a blood metabolite panel could improve non-invasive screening if validated
Population Reach	8	MASLD affects 25-30% of adults globally (2 billion people); screening unmet need is substantial
Implementation Speed	4	n=179; requires external validation; metabolomic profiling is not yet a routine clinical test
Evidence Strength	5	Observational; n=179; seven-algorithm comparison; no external validation; abstract-only; classification_confidence = high

Key quantitative result: High discrimination accuracy (specific AUC not extracted); kynurenine and neopterin as top markers. External validation: None confirmed. Main limitation: Small n=179; single-center; metabolomics not clinically standardized; no cost-effectiveness data. Equity: MASLD disproportionately affects certain ethnic groups (Hispanic, South Asian); a blood-based test could improve equitable access to diagnosis. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 26 — Calabrò et al., ML precision antidepressant prescribing (PMID 42801835)

Dimension	Score	Rationale
Scientific Novelty	6	Using real-world prescribing patterns as training data for ML-based precision prescribing is a novel methodological approach
Clinical Relevance	6	Treatment-resistant depression and trial-and-error prescribing are major burdens; a validated tool could meaningfully reduce time-to-effective treatment
Population Reach	8	~280 million people live with depression globally; antidepressant prescribing is near-universal in developed countries
Implementation Speed	4	Similarity-based approach "appreciable" but not clearly superior; prospective validation needed before clinical use
Evidence Strength	4	Retrospective real-world data; unclear sample size; concordance metric undefined in abstract; classification_confidence = medium

Key quantitative result: "Appreciable concordance" for similarity-based prescribing approach (quantitative metrics not extracted). External validation: Not confirmed. Main limitation: Abstract-only; concordance metric poorly defined; retrospective prescribing patterns may encode biases; no clinical outcome validation. Equity: If validated, could reduce disparities in antidepressant treatment by standardizing prescribing; currently, prescribing is heavily influenced by provider experience and specialty. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 27 — Zhu et al., conversion window in hepatocellular carcinoma (PMID 42802049)

Dimension	Score	Rationale
Scientific Novelty	5	Conversion therapy in HCC is an active area; this expert perspective reframes the decision framework but does not present new data
Clinical Relevance	6	HCC management is increasingly complex with effective systemic therapies; multidisciplinary timing criteria for surgery are a genuine clinical need
Population Reach	7	~900,000 new HCC cases per year globally; highly prevalent in Asia and sub-Saharan Africa
Implementation Speed	4	Expert commentary; future trials and prospective registries recommended; not immediately practice-changing
Evidence Strength	3	Expert perspective/clinical commentary; no primary data; classification_confidence = medium

Key quantitative result: None; conceptual framework paper. External validation: N/A. Main limitation: Opinion piece; no primary data; framework requires prospective validation. Equity: HCC disproportionately affects patients with viral hepatitis in lower-income countries where systemic therapies may be inaccessible. Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 28 — Hamashoji et al., serum chloride and MACE in peritoneal dialysis (PMID 42801415)

Dimension	Score	Rationale
Scientific Novelty	6	Serum chloride as an independent cardiovascular risk marker in PD patients, adjusted for sodium, is a specific and underexplored finding
Clinical Relevance	6	If replicated, serum chloride could be added to routine PD monitoring with zero additional cost
Population Reach	4	Peritoneal dialysis is used by ~200,000 patients globally; specialized population
Implementation Speed	7	Serum chloride is measured on every basic metabolic panel; no new testing required
Evidence Strength	6	Multicenter registry n=1,043; prospective cohort; adjusted analysis; abstract-only; classification_confidence = high

Key quantitative result: Lower serum chloride independently associated with higher MACE risk in PD patients (specific HR not extracted). External validation: Multicenter registry; not independently replicated externally. Main limitation: Single-country (Japan); PD-specific; generalizability to hemodialysis patients unclear. Equity: PD patients in lower-resource settings may benefit most from a zero-cost risk marker. Evidence Maturity (confirmed/revised): Validated ✓

---

Article 29 — Chung et al., ultrasound-guided vs open carpal tunnel release (PMID 42802089)

Dimension	Score	Rationale
Scientific Novelty	4	Systematic review of a well-established comparison; -13.9 days faster return to normal activities is the key quantitative contribution
Clinical Relevance	6	Carpal tunnel syndrome is extremely common; faster recovery translates directly to reduced disability and economic impact
Population Reach	8	CTS is one of the most common surgical conditions globally (~500,000 surgeries/year in the US alone)
Implementation Speed	7	Ultrasound-guided CTR is already practiced; this systematic review provides meta-level evidence to support wider adoption
Evidence Strength	7	Systematic review and meta-analysis of prospective controlled studies; higher design quality than individual studies

Key quantitative result: UGCTR associated with earlier return to normal activities by 13.9 days (95% CI: -27.5 to -0.3); no significant differences in other outcomes. External validation: Meta-analysis of multiple studies provides natural external validation. Main limitation: Wide confidence interval (borderline significance); heterogeneity across included studies not reported in abstract; cost-effectiveness not assessed. Equity: Faster recovery reduces lost wages — particularly relevant for manual workers, who represent the highest-risk occupational group for CTS. Evidence Maturity (confirmed/revised): Validated ✓

---

Article 30 — Lv & Du, exosomal signaling in esophageal cancer (PMID 42801943)

Dimension	Score	Rationale
Scientific Novelty	4	Narrative review of a well-reviewed topic (tumor-derived exosomes); synthesis is competent but not a primary discovery
Clinical Relevance	4	Mechanism-focused review; no new clinical data; translation is speculative
Population Reach	6	Esophageal cancer: ~600,000 new cases/year globally; high mortality; surveillance in high-incidence regions critical
Implementation Speed	2	Research review; no clinical tool developed or validated
Evidence Strength	3	Narrative review; no systematic methodology; classification_confidence = medium

Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 31 — Abe et al., intratumoral heterogeneity gastric cancer (PMID 42802061)

Dimension	Score	Rationale
Scientific Novelty	7	Spatial heterogeneity between differentiated and undifferentiated components with distinct dMMR implications is a specific and methodologically interesting contribution
Clinical Relevance	5	Relevant to biomarker-guided therapy (MSI/dMMR testing, HER2); very small sample limits clinical translation
Population Reach	5	Gastric cancer: ~1 million new cases/year globally; 4th most common cancer
Implementation Speed	3	n=5 tumors; pilot study; requires validation in larger cohorts before clinical application
Evidence Strength	3	n=5; exploratory pilot; classification_confidence = high

Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 32 — Gong et al., multi-omics cancer driver discovery (PMID 42801638)

Dimension	Score	Rationale
Scientific Novelty	7	Novel graph-based heterophilic network disentanglement for multi-omics integration is technically innovative
Clinical Relevance	3	Computational; non-human study cap applies; not yet clinically validated
Population Reach	5	Broad cancer applicability in principle
Implementation Speed	2	Computational only; requires extensive experimental and clinical validation
Evidence Strength	3	Computational benchmark; in vitro classification

Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 33 — Narvel et al., STAT6 review, precision immunotherapy (PMID 42801147)

Dimension	Score	Rationale
Scientific Novelty	5	STAT6 as an immunotherapy target is an emerging area; IL-4/IL-13 pathway inhibition (dupilumab) is established in atopy; cancer application is less developed
Clinical Relevance	4	Mechanistic review; no clinical data; treatment implications speculative
Population Reach	5	If STAT6 targeting proves useful across cancer types, broad applicability; currently speculative
Implementation Speed	2	No approved STAT6-targeted cancer therapy; years from clinical translation
Evidence Strength	3	Narrative review; mixed-species scope

Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 34 — Mokabberi et al., hyperthermia + pemetrexed in A549 (PMID 42801783)

Dimension	Score	Rationale
Scientific Novelty	5	Thermochemotherapy in lung cancer is not new; the specific miRNA mechanism (hsa-MiR-548c-3p upregulation, TYMS downregulation) adds mechanistic specificity
Clinical Relevance	2	In vitro only; non-human cap applied; clinical translation of hyperthermia-chemotherapy combinations is limited
Population Reach	5	NSCLC is the leading cause of cancer death; potential broad relevance if translated
Implementation Speed	1	Lab stage; no clinical validation
Evidence Strength	3	In vitro; single cell line; non-human cap

Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 35 — Vijiakumar et al., EMT/immune checkpoint markers in oral leukoplakia (PMID 42802034)

Dimension	Score	Rationale
Scientific Novelty	5	PD-1/PD-L1 as prognostic markers in oral leukoplakia is a logical but not groundbreaking extension of checkpoint biology
Clinical Relevance	5	Oral leukoplakia transformation is an important clinical problem; PD-L1 association "may warrant further validation" — not yet practice-changing
Population Reach	5	Oral leukoplakia prevalence ~2-3% globally; oral cancer has high burden in South/Southeast Asia
Implementation Speed	4	IHC for PD-L1 is available; but clinical utility not yet established
Evidence Strength	4	Retrospective biomarker study; sample size unconfirmed; abstract-only; classification_confidence = medium

Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 36 — Zaidi et al., liver enzymes in pediatric IBD on biologics (PMID 42801947)

Dimension	Score	Rationale
Scientific Novelty	4	Clinical review/practice guidance; synthesizes existing knowledge without new primary data
Clinical Relevance	6	Common clinical challenge for pediatric gastroenterologists; practical framework has immediate utility
Population Reach	5	Pediatric IBD prevalence rising globally; biologics now standard of care
Implementation Speed	7	Framework is immediately implementable in clinical practice
Evidence Strength	4	Clinical review; no primary data; classification_confidence = medium

Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 37 — Kitsiou, vulnerability in frail elderly post-fall (PMID 42801732)

Dimension	Score	Rationale
Scientific Novelty	4	Philosophical/conceptual exploration of vulnerability; not empirically novel
Clinical Relevance	5	Nursing ethics framework useful for care team training and policy; not directly practice-changing for clinical outcomes
Population Reach	7	Falls in the elderly affect millions globally and are a leading cause of injury and death
Implementation Speed	6	Ethical frameworks can be incorporated into nursing education and care protocols relatively quickly
Evidence Strength	3	Qualitative/philosophical; no quantitative outcomes

Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 38 — Sawamura et al., lipodystrophy + fulminant T1DM case report (PMID 42802057)

Dimension	Score	Rationale
Scientific Novelty	5	Very rare combination; metreleptin therapy with long-term follow-up adds to a very sparse literature
Clinical Relevance	4	Case report; rare disease; not generalizable
Population Reach	1	Acquired generalized lipodystrophy: estimated <500 cases worldwide
Implementation Speed	4	Metreleptin is approved for generalized lipodystrophy; T1DM complication management is generalizable
Evidence Strength	2	Case report; n=1

Evidence Maturity (confirmed/revised): Exploratory ✓

---

Article 39 — Benedetto et al., DCD heart transplantation at noncardiac hospital (PMID 42802092)

Dimension	Score	Rationale
Scientific Novelty	6	Mobile perfusion team enabling DCD heart procurement at non-cardiac surgery hospitals is an organizational innovation with genuine programmatic novelty
Clinical Relevance	5	Addresses heart donor organ supply; could expand DCD heart program reach; case series context limits conclusions
Population Reach	5	Heart transplant waitlist ~3,000-4,000 in the US; globally significant organ shortage
Implementation Speed	5	Requires mobile team infrastructure, training, and regulatory framework; regionally applicable in Italy currently
Evidence Strength	3	Case series/report; n=1 detailed + 19 donors in series; classification_confidence = medium

Evidence Maturity (confirmed/revised): Exploratory ✓

---

---

Composite Impact Score Calculation

Weights: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%

Rank	Article (PMID)	Clinical Rel.	Pop. Reach	Sci. Novelty	Impl. Speed	Evid. Strength	Impact Score	Triage Score	Study Design	Priority Flag
1	HPV E6 mRNA triage, LMIC cervical cancer (42801821)	8	9	6	5	5	7.20	8	Assay dev/validation	🔴
2	cfDNA methylation, PCa vs BPH (42801083)	8	8	7	4	5	7.05	8	Observational biomarker	🔴
3	Perioperative durvalumab, Japanese NSCLC AEGEAN (42802029)	8	7	6	7	7	7.25	8	Phase 3 RCT subgroup	🟠
4	Nocturia and CKM syndrome mortality (42801412)	7	9	6	7	6	7.20	7	Cross-sectional + cohort	⬜
5	N-AVD vs BV-AVD Hodgkin lymphoma (42802099)	8	6	5	8	6	7.00	7	Multicenter retrospective cohort	⬜
6	ctDNA methylation prostate cancer staging (42801146)	7	7	7	4	5	6.45	7	Observational biomarker	⬜
7	Respiratory viral infections post-CAR-T (42801991)	8	6	6	7	6	6.90	7	Retrospective cohort	⬜
8	Hypertensive retinopathy and WMH progression (42801966)	7	8	6	7	7	7.10	7	Prospective longitudinal cohort	🟢
9	High-frequency exercise for depression, RCT (42802098)	7	7	5	8	7	6.90	7	RCT (single-blind)	🟢
10	ApoB-LDL discordance, NHANES (42801018)	7	8	5	7	5	6.70	7	Cross-sectional NHANES	🟢
11	Resolved HBV and DLBCL outcomes, JCOG0601 (42801438)	7	7	5	7	7	6.70	7	RCT supplementary analysis	⬜
12	Digital PCR BAP1/MTAP mesothelioma (42801547)	7	4	7	5	6	6.00	8	Retrospective validation	🔴
13	DOORS-GHF geriatric hip fracture score (42802133)	7	8	5	7	6	6.80	7	Prospective dev/validation	🟢
14	Alzheimer's disease review, lecanemab/donanemab (42801246)	7	9	3	5	4	6.20	7	Narrative review	🟢
15	Kidney function and cognitive impairment, CLHLS (42802142)	6	9	5	6	6	6.55	7	Longitudinal cohort	⬜
16	Intrathecal dexamethasone in FIRES (42801909)	7	3	7	5	4	5.60	7	Review/case series	🟡
17	EGPA diagnostic delay (42801333)	7	3	6	6	5	5.60	7	Retrospective single-center	🟡
18	Gastric GIST CT DL risk stratification (42801804)	7	5	6	5	6	6.10	6	Multicenter retrospective	⬜
19	ML metabolomics for MASLD (42801942)	6	8	6	4	5	6.10	6	Observational ML study	⬜
20	PCR-free biosensor cfDNA methylation, ovarian cancer (42801800)	3	6	8	2	4	4.50	7	In vitro proof-of-concept	⚪
21	Serum chloride and MACE in PD (42801415)	6	4	6	7	6	5.75	6	Multicenter cohort	⬜
22	Food noise prevalence, US adults (42801078)	5	8	6	5	5	5.95	7	Cross-sectional survey	⬜
23	Ultrasound-guided vs open carpal tunnel release (42802089)	6	8	4	7	7	6.35	6	Systematic review/meta-analysis	🟢
24	FLT vs FDG PET for CNS lymphoma vs GBM (42801444)	6	4	6	4	5	5.30	6	Retrospective diagnostic	⬜
25	AI lesion segmentation lymphoma FDG PET/CT (42802086)	6	6	5	5	5	5.65	6	Retrospective validation	⬜
26	ML MRI Friedreich ataxia progression (42802091)	5	3	7	4	5	4.90	6	Longitudinal ML study	⬜
27	ML precision antidepressant prescribing (42801835)	6	8	6	4	4	5.90	6	Retrospective RWD ML	⬜
28	PABCNet super-resolution coronary MRA (42801839)	5	7	7	3	5	5.55	6	Technical validation	⬜
29	Conversion window in HCC (42802049)	6	7	5	4	3	5.40	6	Expert perspective	⬜
30	Intratumoral heterogeneity gastric cancer (42802061)	5	5	7	3	3	4.80	5	Genomic pilot (n=5)	⬜
31	EGPA Vulnerability frail elderly post-fall (42801732)	5	7	4	6	3	5.10	5	Qualitative/mixed	🟡
32	Exosomal signaling esophageal cancer (42801943)	4	6	4	2	3	4.10	5	Narrative review	⬜
33	Multi-omics cancer driver discovery (42801638)	3	5	7	2	3	4.00	5	Computational	⚪
34	STAT6 review, precision immunotherapy (42801147)	4	5	5	2	3	4.00	5	Narrative review	⬜
35	EMT/immune checkpoint, oral leukoplakia (42802034)	5	5	5	4	4	4.75	5	Retrospective biomarker	⬜
36	Liver enzymes in pediatric IBD on biologics (42801947)	6	5	4	7	4	5.50	5	Clinical review	⬜
37	Hyperthermia + pemetrexed in A549 (42801783)	2	5	5	1	3	3.30	5	In vitro preclinical	⚪
38	Lipodystrophy + fulminant T1DM case report (42802057)	4	1	5	4	2	3.15	4	Case report	⬜
39	DCD heart transplantation at noncardiac hospital (42802092)	5	5	6	5	3	4.95	4	Case series	⬜

---

Re-ranking with Tie-breaker Resolution

After applying tie-breakers (Clinical Relevance → Evidence Strength → Implementation Speed), final order for top 10:

Final Rank	Article	Impact Score
1	Perioperative durvalumab NSCLC AEGEAN (42802029)	7.25
2	HPV E6 mRNA triage LMIC cervical cancer (42801821)	7.20
3	Nocturia and CKM syndrome mortality (42801412)	7.20
4	Hypertensive retinopathy and WMH progression (42801966)	7.10
5	cfDNA methylation PCa vs BPH (42801083)	7.05
6	N-AVD vs BV-AVD Hodgkin lymphoma (42802099)	7.00
7	Respiratory viral infections post-CAR-T (42801991)	6.90
8	High-frequency exercise for depression RCT (42802098)	6.90
9	DOORS-GHF geriatric hip fracture score (42802133)	6.80
10	ApoB-LDL discordance NHANES (42801018)	6.70

---

Rank #1 Justification

Mitsudomi et al., perioperative durvalumab in Japanese NSCLC AEGEAN (PMID 42802029) ranks first on the composite weighted score and satisfies all ranking eligibility criteria: Evidence Strength ≥6 (scored 7 for a Phase 3 RCT framework), peer-reviewed, and classified as Potentially Practice-Changing. Its Clinical Relevance of 8 reflects that perioperative immunotherapy is one of the most actively contested treatment decisions in thoracic oncology today, and Japanese-specific data are directly actionable for a market where durvalumab is already under regulatory consideration in this context. The global AEGEAN trial established the efficacy signal; this subgroup provides the ethnic-specific confirmatory data that oncologists and regulators in Japan need. Implementation Speed of 7 reflects the fact that the drug is already available and the evidence integration step is well underway. The main limitation — n=79, exploratory subgroup — is real but mitigated by consistency with the global trial.

Why it matters: Hundreds of thousands of patients globally have resectable NSCLC diagnosed each year. This Japanese subgroup analysis of a pivotal Phase 3 trial confirms that perioperative PD-L1 blockade with durvalumab improves event-free survival and pathological complete response in Asian patients — directly addressing a population underrepresented in the original global dataset and providing regulators and clinicians with the data needed to expand access to this approach.

---

Note on Internal Conflicts

Liquid biopsy for prostate cancer: Articles 1 and 9 both address cfDNA/ctDNA methylation in prostate cancer but address different clinical questions — diagnostic discrimination (PCa vs BPH) vs. disease stratification (localized vs. metastatic). These are complementary rather than conflicting, though both are exploratory and would require independent validation before clinical use.

Cervical cancer triage: Article 2 (HPV E6 mRNA) occupies a different niche from existing commercial triage tools (colposcopy, HPV genotyping, p16/Ki-67) — it is specifically positioned for LMIC resource-constrained settings. No conflict with existing literature; rather, an additive equity-focused contribution.

---

---

PHASE 4 — Deep Dives

---

---

[HOOK]

Cervical cancer is one of the most preventable cancers in the world — and yet it kills approximately 350,000 women every year, almost all of them in low- and middle-income countries. The tools to stop it exist. The problem is that the best ones never reach the women who need them most. A new study from Bangladesh asks: what if we could build a smarter, more affordable test that tells doctors exactly which women are on the path to cancer?

[THE DISCOVERY]

Researchers developed an in-house semi-quantitative real-time PCR assay that measures how much HPV-16 or HPV-18 E6 messenger RNA is present in cervical samples — specifically, how much it's changed from a reference point (the "fold change"). In their study of HPV-positive women, a fold-change cutoff of 0.648 or above could identify women with high-grade cervical lesions or invasive cancer with 95.24% sensitivity and 86.36% specificity. In plain terms: the test correctly flagged almost all of the women with serious disease, and correctly cleared the majority of women who didn't have it. That's a better balance than many current triage approaches used in the settings where this assay is intended to work.

[THE SCIENCE BEHIND IT]

The key insight behind this test is biological: when HPV integrates into the human genome and starts driving cells toward cancer, the E6 protein — which degrades the tumor suppressor p53 — gets produced at high levels. Measuring E6 mRNA rather than viral DNA gives you a functional readout of how much the virus is actually "switched on" and transforming cells, rather than just whether the virus is present. The researchers designed their assay to be in-house and semi-quantitative, making it buildable in a reference laboratory without proprietary commercial platforms. One major limitation worth flagging: this is a single-center study from Bangladesh, cohort size is not confirmed in the published abstract, and the performance of any fold-change assay depends on having a reliable reference standard — which may vary across labs and sample types.

[WHO THIS HELPS]

Most directly: HPV-positive women in low- and middle-income countries in South Asia, sub-Saharan Africa, and Latin America, where cervical cancer incidence is highest and where existing triage tools — like colposcopy, which requires trained specialists and expensive equipment — are simply not available at scale. Globally, women in rural areas, women in countries without organized screening programs, and women who access healthcare infrequently are the ones dying from cervical cancer that could have been caught.

[THE REAL-WORLD IMPACT]

If this assay can be externally validated and standardized, it offers a concrete pathway to a "screen and triage" strategy: identify HPV-positive women with a low-cost swab test, then use this E6 mRNA fold-change assay to immediately stratify who needs urgent colposcopy or treatment and who can safely return for follow-up. This could reduce the enormous bottleneck that occurs when every HPV-positive woman is referred for colposcopy — a system that collapses in resource-limited settings. At 95% sensitivity, the test is good enough to serve as a safety net for detecting true high-grade disease. The 86% specificity means some women without serious disease would still be referred, but that's an acceptable trade-off in settings where missing a cancer is catastrophic and unnecessary treatment is the lesser harm.

[WHAT WE STILL DON'T KNOW]

The central unknowns are validation at scale and in diverse populations. Does the E6 fold-change cutoff of 0.648 hold up in women with co-infections, in different HPV prevalence contexts, or when samples are collected by self-sampling rather than clinician swab? Does performance differ across age groups, HIV status, or pregnancy? Is the assay reproducible between different labs using locally sourced reagents? And critically: what happens to the cost-per-test when you remove commercial kit support? These are all answerable questions — but they require multicenter prospective studies in the populations this test is meant to serve.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate — the sensitivity/specificity data are promising and biologically well-grounded, but evidence is still at single-center exploratory stage
• Translation Speed: 5–10 years for broad implementation; faster (2–5 years) if WHO prequalification is pursued and a multi-country validation study is funded
• Barrier Analysis:
  • Regulatory: Assay would need national approval in target countries; WHO prequalification could accelerate
  • Reimbursement: In-house assay design bypasses some commercial pricing barriers, but reagent procurement and cold-chain requirements remain
  • Infrastructure: Real-time PCR machines are present in many district-level reference labs in LMICs but not all
  • Awareness: Requires training of lab technicians and integration into existing screening workflows
  • Equity: This is fundamentally an equity-first intervention — if it doesn't reach rural, low-income women, its impact is limited

[CALL TO ACTION / CLOSING]

Cervical cancer should be a disease of the past — and for women in high-income countries, it nearly is. This simple, adaptable mRNA test is a real step toward closing that gap, and the next move belongs to funders and global health agencies willing to validate it at scale.

---

---

[HOOK]

Pleural mesothelioma is one of medicine's most brutal diagnoses. It arrives late, spreads fast, and has resisted most treatments. Before you can even begin to fight it, you need to prove you're fighting it — and that diagnosis often requires invasive, painful biopsies from deep inside the chest. A new study asks whether the fluid that collects around the lung could do the diagnostic work instead.

[THE DISCOVERY]

Italian researchers tested whether digital PCR — an extremely sensitive method for detecting small differences in DNA copy number — could identify the loss of two key genes, BAP1 and MTAP, directly from the supernatant of pleural fluid samples (the clear liquid spun off after removing cells from the fluid). These two genes are commonly deleted in mesothelioma cells. When they combined this liquid-based digital PCR test with standard immunohistochemistry (IHC) on tissue, they improved diagnostic sensitivity from 86.5% to 91.9%. In six patients where diagnosis had been inconclusive, two showed reduced gene copy numbers — an early hint that the test might one day help resolve exactly the kind of ambiguous case that currently leaves patients in diagnostic limbo.

[THE SCIENCE BEHIND IT]

Digital PCR works by partitioning a DNA sample into thousands of tiny individual reactions and counting the exact number of copies of a target sequence — in this case, the BAP1 and MTAP genes. When copies are lost (as happens in mesothelioma due to deletion), the count drops. The clever twist here is the sample source: instead of using tissue biopsy or blood, the researchers used the cell-free DNA floating in the supernatant of pleural effusion — the fluid that builds up in the chest cavity in mesothelioma patients. This fluid is often collected anyway during standard care (to relieve breathlessness), so no additional invasive procedure is needed. The main limitation is the very small sample: 37 confirmed mesothelioma patients, all already diagnosed. The harder clinical question — how does this test perform when the diagnosis is genuinely uncertain? — is only touched on with six prospective cases.

[WHO THIS HELPS]

Mesothelioma patients — primarily men in their 60s and 70s with a history of occupational asbestos exposure, including shipbuilders, construction workers, plumbers, and miners. These patients are often working-class individuals who were exposed decades before safety regulations caught up, and who now face a disease where delayed diagnosis is almost universal. The test could also be valuable in the small number of women and younger patients who develop mesothelioma without clear asbestos history, where diagnosis is often especially delayed.

[THE REAL-WORLD IMPACT]

The immediate potential impact is a reduction in the number of repeat biopsies required to confirm mesothelioma diagnosis. Thoracoscopy and CT-guided biopsy carry real procedural risks in elderly patients with compromised lung function. If digital PCR on routinely collected pleural fluid can push diagnostic sensitivity above 90% in combination with IHC, it gives pathologists a non-invasive second opinion — particularly valuable when IHC results are equivocal. Further down the line, if the test can be validated in a truly prospective population of "diagnosis unknown" patients, it could shorten the diagnostic pathway from months to weeks, getting patients into treatment faster.

[WHAT WE STILL DON'T KNOW]

The fundamental unanswered question is: how does this test perform when you don't already know the diagnosis? The retrospective design means all 37 patients were confirmed mesothelioma — there's no data on false positives in patients with benign pleural disease, reactive mesothelial proliferations, or metastatic adenocarcinoma (the main diagnostic mimics). The prospective 6-patient substudy is encouraging but far too small to draw conclusions. We also don't know the optimal thresholds for calling copy-number loss "positive," how the test performs across different mesothelioma subtypes, or whether the assay can detect early-stage disease before clinical presentation.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate — the biology is sound, the sensitivity gain is real, and the sample source is clinically elegant; but the evidence base is very small
• Translation Speed: 5–10 years to prospective validation and routine use; digital PCR platforms are increasingly available but not ubiquitous
• Barrier Analysis:
  • Regulatory: Digital PCR for copy-number loss in pleural fluid would require prospective diagnostic accuracy studies and likely regulatory clearance as a companion diagnostic aid
  • Reimbursement: Digital PCR is expensive; reimbursement pathways for liquid biopsy in mesothelioma are not established
  • Cost: Digital PCR platforms cost $50,000–$150,000; reagent costs per sample are falling but still significant
  • Infrastructure: Requires molecular pathology laboratories; not available in community hospitals
  • Equity: The disease disproportionately affects blue-collar workers but treatment occurs at academic centers; access equity depends on referral patterns

[CALL TO ACTION / CLOSING]

When pleural fluid is already being collected to help a mesothelioma patient breathe, using that same sample to sharpen the diagnosis is the kind of elegant clinical logic that deserves larger-scale testing. The next step is a prospective study in diagnostically ambiguous cases — and it can't come soon enough for a disease where every week of delay matters.

---

---

[HOOK]

Every year, hundreds of thousands of men with elevated PSA results face a dilemma: is this cancer, or is it just an enlarged prostate? The PSA test can't tell the difference reliably, and the answer often comes from a needle biopsy that carries real risks and causes real anxiety. What if a blood test could make that call instead?

[THE DISCOVERY]

Researchers in South Korea developed a cell-free DNA methylation classifier designed to distinguish prostate cancer from benign prostatic hyperplasia non-invasively, using a blood sample. Cell-free DNA — tiny fragments of DNA shed by cells into the bloodstream — carries epigenetic "tags" called methylation marks that differ between normal, benign, and cancerous tissue. The team identified methylation patterns enriched near gene promoters involved in developmental signaling, transcription factor activity, and chromatin remodeling in cancer, while gene-body methylation tracked RNA processing differences. Together, these patterns form a biological fingerprint the classifier uses to separate cancer from benign disease — without ever inserting a needle.

[THE SCIENCE BEHIND IT]

The study is an observational biomarker development and validation study — the researchers identified differentially methylated regions, built a classifier, and tested it in a patient cohort of men with suspected prostate disease (though the cohort size is not reported in the abstract). The approach builds on the growing field of "epigenetic liquid biopsy," where methylation patterns in cell-free DNA are used as surrogates for tissue biology. The biological rationale is well-founded: prostate cancer drives global and gene-specific methylation changes, and cfDNA captures fragments of tumor DNA that reflect those changes. The primary limitation of this paper, as reviewed, is that it's abstract-only — we don't know the sensitivity, specificity, AUC, or cohort composition. Without those numbers, we can't yet assess how this classifier compares to existing tools like the Prostate Health Index, 4Kscore, or multiparametric MRI.

[WHO THIS HELPS]

Most directly: men with elevated PSA results in the "diagnostic gray zone" — typically PSA 4–10 ng/mL — where the probability of cancer is real but not dominant, and where clinicians and patients currently face the choice between biopsy (with its infection, bleeding, and psychological burden) and watchful waiting (with the anxiety of delayed diagnosis). Black men, who face both higher prostate cancer incidence and higher rates of PSA non-specificity, stand to benefit disproportionately from a better discriminator — if the test is validated across diverse populations and made accessible.

[THE REAL-WORLD IMPACT]

If validated, a cfDNA methylation classifier could slot into the diagnostic pathway between an elevated PSA result and a decision about biopsy. Men whose classifier score is low could safely defer biopsy; men with high scores could be fast-tracked. This could substantially reduce the number of unnecessary biopsies performed annually — estimated at over one million in the US alone — reducing infection risk, sepsis hospitalizations, anxiety, and cost. For the healthcare system, it could reduce spending on unnecessary pathology, urology visits, and complication management. For patients, it could replace a week of fear-filled waiting for biopsy results with a blood draw and a faster answer.

[WHAT WE STILL DON'T KNOW]

Almost everything quantitative remains unpublished or unextracted. We don't know the test's sensitivity or specificity. We don't know how it performs in men on active surveillance, or in those with prior negative biopsies. We don't know whether its performance holds across different ethnic groups, PSA ranges, or prostate volumes. We also don't know whether the classifier adds information beyond — or independent of — multiparametric MRI, which is increasingly used as a pre-biopsy triage tool in high-income settings. Without a prospective head-to-head comparison with existing risk calculators and MRI, it's premature to predict where this test would fit in clinical workflows.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate — biologically plausible, methodologically appropriate, published in peer-reviewed literature; but quantitative performance data not yet available for independent assessment
• Translation Speed: 5–10 years to prospective multi-center validation and regulatory submission; faster if major diagnostic companies partner for development
• Barrier Analysis:
  • Regulatory: Would need prospective diagnostic accuracy data, FDA De Novo or 510(k) submission; companion analytic validity requirements
  • Reimbursement: cfDNA-based cancer detection tests face evolving payer coverage landscapes; precedent exists (Galleri, Oncotype) but is contested
  • Cost: Methylation sequencing is currently more expensive than protein biomarker testing; cost reduction with targeted panels is plausible
  • Infrastructure: Requires clinical-grade methylation profiling laboratory; not universally available
  • Equity: PSA over-testing and over-biopsy disproportionately harms Black men; a specific validation effort in this population is essential before broad deployment

[CALL TO ACTION / CLOSING]

The PSA test has been telling us for decades that it needs help. A blood-based epigenetic classifier that can tell cancer from a benign enlarged prostate is a genuinely compelling idea — and now the work of rigorous, diverse-population validation begins.